Malignant pericardial tamponade in a patient with hormone-refractory prostate cancer

被引:0
|
作者
Tomonori Minagawa
Yasushi Murata
Shinichiro Uchikawa
Takeshi Uehara
机构
[1] Azumino Red Cross Hospital,Department of Urology
[2] Azumino Red Cross Hospital,Department of Cardiovascular Medicine
[3] Shinshu University School of Medicine,Department of Laboratory Medicine
关键词
Prostate cancer; Pericardial metastasis; Prostate-specific antigen;
D O I
暂无
中图分类号
学科分类号
摘要
An 82-year-old man who was receiving treatment for prostate cancer and cholangiocellular carcinoma was admitted to our hospital because of chest discomfort and dyspnea. At the time of admission, 16 months after the start of hormone therapy, the prostate-specific antigen level was 454.08 ng/ml. Chest radiography revealed cardiomegaly, and ultrasonography demonstrated significant pericardial effusion. Pericardiocentesis yielded a hemorrhagic exudate, and a routine cytological study revealed malignant cells. It was difficult to determine whether these cells had originated from the prostate cancer or the cholangiocellular carcinoma. However, immunohistochemical analysis of a cell-block section of the pericardial effusion allowed a diagnosis of pericardial metastasis from the prostate cancer. After drainage and intrapericardial injection of cisplatin, the amount of effusion was decreased. After removal of the pericardial drain, the patient was discharged, but the pericardial effusion was found to have accumulated again 1 month later.
引用
收藏
页码:101 / 103
页数:2
相关论文
共 50 条
  • [1] Malignant pericardial tamponade in a patient with hormone-refractory prostate cancer
    Minagawa, Tomonori
    Murata, Yasushi
    Uchikawa, Shinichiro
    Uehara, Takeshi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2010, 15 (01) : 101 - 103
  • [2] Hormone-Refractory prostate cancer
    Rini B.I.
    Small E.J.
    Current Treatment Options in Oncology, 2002, 3 (5) : 437 - 446
  • [3] Hormone-refractory prostate cancer
    Alexandre, I.
    Rixe, O.
    ANNALES D UROLOGIE, 2007, 41 (02) : 47 - 55
  • [4] Chemotherapy of the hormone-refractory prostate cancer
    Heine, K
    Wolff, JM
    AKTUELLE UROLOGIE, 2004, 35 (03) : 209 - 214
  • [5] Management of hormone-refractory prostate cancer
    Dogliotti, L
    Mosca, A
    TUMORI, 2003, : S147 - S149
  • [6] Taxanes in hormone-refractory prostate cancer
    Kang, MH
    Figg, WD
    Dahut, W
    CANCER PRACTICE, 1999, 7 (05) : 270 - 272
  • [7] Therapy of hormone-refractory prostate cancer
    Heidenreich, A
    UROLOGE, 2005, 44 (12): : 1481 - 1494
  • [8] Satraplatin for hormone-refractory prostate cancer
    Kerr, Cathel
    LANCET ONCOLOGY, 2007, 8 (04): : 290 - 290
  • [9] Chemotherapy for hormone-refractory prostate cancer
    Shelley, Mike
    Harrison, Craig
    Coles, Bernadette
    Staffurth, John
    Wilt, Timothy J.
    Mason, Malcolm D.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (04):
  • [10] Chemotherapy in hormone-refractory prostate cancer
    de Wit, Ronald
    BJU INTERNATIONAL, 2008, 101 : 11 - 15